Rappta
3 known investors
Rappta Therapeutics develops a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor enzyme PP2A (protein phosphatase 2A). Its PP2A-reactivating platform targets protein hyperphosphorylation implicated in cancer and other diseases such as neurodegeneration.
Investors · 3
In the news
Frequently asked questions
- What does Rappta do?
- Rappta Therapeutics develops a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor enzyme PP2A (protein phosphatase 2A). Its PP2A-reactivating platform targets protein hyperphosphorylation implicated in cancer and other diseases such as neurodegeneration.
- Who are Rappta's investors?
- Rappta's investors include Advent Life Sciences, Novartis Venture Fund, Novo Holdings.